Gilead, Roche, Roche deal

The companies will collaborate on the development of therapies to treat and prevent viral influenza. Under the deal, Roche receives exclusive worldwide rights to GILD's neuraminidase inhibitors, including GS 4104, which has demonstrated activity in preclinical models against a broad spectrum of influenza viruses, GILD said.

Roche will make an initial $10 million cash payment, which GILD expects to book as third quarter revenue. Roche also will fund all R&D costs. GILD will receive a royalty rate in the mid-teens on GS4104, and could receive up to $40 million in milestone payments. ...